TY  - RPRT
TI  - Technology evaluation: gemtuzumab ozogamicin, Celltech Group.
AU  - I Niculescu-Duvaz
PY  - 2000
UR  - https://pubmed.ncbi.nlm.nih.gov/11249747/
ID  - 11249747
ER  -